Canify
Canify AG is a German licensed pharmaceutical company that imports, EU-GMP processes, and distributes medical cannabis to German pharmacies and European pharmaceutical wholesalers across multiple product tiers, with a digital marketplace expansion in 2026.
- Company typePrivate
- Founded2022
- HeadquartersVejle, Denmark
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Canify does
Canify AG is a German licensed pharmaceutical company focused on the import, EU-GMP certified processing, packaging, and distribution of medical cannabis to pharmacies and pharmaceutical wholesalers across Europe. The company was formed in June 2022 through the merger of Bavaria Weed GmbH (Herrsching, Germany) and Canify AS (Denmark), and operates from a headquarters in Herrsching am Ammersee with production at a former NATO bunker facility in Leipheim that is qualified to EU-GMP and GDP standards and can store up to two tons of cannabis. Its product portfolio spans dried cannabis flowers across tiers (Canify Basic, Pure, Choice, Craft), cannabis extracts co-developed with Somai, exclusive Tikun Olam Europe cultivars distributed via Dopiopharm, a sublingual cannabinoid spray (Xatepa), and the Canify Sun line sourced from Uruguay — all underpinned by a multi-jurisdictional supplier base in Lesotho, Portugal, Colombia, Greece, and Uruguay.
Revenue is generated primarily through unit-priced B2B sales of cannabis flowers and extracts to validated German pharmacies (priced at €2.65–€9.95 per gram) and European pharmaceutical wholesalers, supplemented by contract manufacturing and market access services for third-party cannabis producers covering supplier qualification, laboratory analysis, GMP processing, batch release, warehousing, and distribution. Distribution is executed through a direct pharmacy sales infrastructure (hotline, Fachkreis portal, DocCheck validation) supported by Phoenix BTM for BtM-compliant logistics, with the CATHAROS digital marketplace — launching in 2026 in partnership with IhreApotheken.de — adding a patient-facing channel connected to up to 7,500 pharmacies. As of 2025, the company reported €15.5M in revenue for the first nine months (up 250% year-over-year) with over 7 tons processed, and is pursuing pre-IPO equity financing alongside a merger with MG Health to integrate cultivation upstream.
Canify firmographics
Firmographics- Name
- Canify
- Legal name
- Canify AG
- Website
- https://canify.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Canify AG is a German licensed pharmaceutical company that imports, EU-GMP processes, and distributes medical cannabis to German pharmacies and European pharmaceutical wholesalers across multiple product tiers, with a digital marketplace expansion in 2026.
- Ownership category
- akta.pro rank
Canify industry classification
Industry- Product category
- Medical Cannabis Pharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Medical Cannabis Delivery & Online Ordering (CRANAGAG)
- akta.pro secondary industries
- Cannabis Wholesale Distribution (Flower, Extracts, Edibles) (CRAOAIAF), Third-Party White-Label Ordering & Delivery Platforms (SaaS + Logistics) (CRANAGAF), Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)
Keywords
Where Canify is headquartered
LocationHeadquarters
- HQ city
- Vejle
- HQ country
- Denmark
- HQ region
- Europe
Offices3 records
Markets served
Canify business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Medical Cannabis Product Sales: Sale of dried cannabis flowers and cannabis extracts to pharmacies and wholesalers across Europe. Products include various THC/CBD ratios and cultivars sourced from international cultivators.
- Contract Manufacturing Services (CMO): Full-service solutions for third-party medical cannabis products including supplier qualification, laboratory analysis, stability testing, import, GMP processing, batch release, warehousing and distribution.
- Market Access Platform Services: Consulting services for market access including EU GDP license acquisition, EU-GACP certification, digital quality management systems, and product sourcing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Canify Basic - Standard cannabis products |
| Unit Pricing | Pay-as-you-go | Canify Pure - Premium processed products |
| Unit Pricing | Pay-as-you-go | Canify Choice - Selected cultivars |
| Unit Pricing | Pay-as-you-go | Canify Craft - Premium hand-selected flowers |
| Unit Pricing | Pay-as-you-go | Dopiopharm Products - Tikun Olam Europe cultivars |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels6 records
Canify product offering
Product offeringCore offering
Canify AG manufactures and distributes EU-GMP and GDP-certified medical cannabis products — dried cannabis flowers and cannabinoid extracts — to pharmacies and pharmaceutical wholesalers across Europe. In addition to its own product portfolio, the company offers contract manufacturing (CMO) and market-access services for third-party cannabis producers, covering supplier qualification, GMP processing, laboratory analysis, batch release, warehousing, and distribution from its former-NATO-bunker production facility in Leipheim, Germany.
Differentiator
Problem solved
Functional benefit
Brands
- Canify Pure: Premium cannabis product line
- Canify Basic
- Canify Choice
- Canify Craft
- Xatepa
- Canify Sun
- Somai Canify Cannabis Extracts
- Ghostdrops
- CATHAROS
Products and services
- Canify Pharma — Medical Cannabis Flowers & Extracts (Canify Basic / Pure / Choice / Craft / Canify Sun / Ghostdrops) EU-GMP and GDP-certified medical cannabis flowers and extracts sold to licensed German pharmacies and European pharmaceutical wholesalers. Products span multiple THC/CBD ratios and cultivars sourced from international cultivation partners (MG Health, Somai, Clever Leaves, Tikun Olam Europe, Fotmer).
- Xatepa Sublingualspray Rezepturarzneimittel cannabinoid-based prescription medicine in sublingual spray form, using an innovative formulation technology for faster active-ingredient absorption versus other delivery methods. Marketed to pharmacies dispensing medical cannabis prescriptions.
- Somai Canify Cannabis Extracts Differentiated cannabis extract line developed with SOMAI Pharmaceuticals featuring an additional purification step, sold in various THC/CBD ratios to German pharmacies under the "Somai Canify Cannabisextrakt" brand.
- Dopiopharm Tikun Olam Europe Cultivars Distribution of Tikun Olam Europe's medical cannabis cultivars to the German market via Dopiopharm GmbH partnership, including Tikun Erez, Midnight, GNC, Noga, OZ, and CAP J varieties.
- CATHAROS Digital Marketplace Pharmacy-centric digital marketplace connecting medical cannabis patients with a network of up to 7,500 participating German pharmacies, ensuring legally compliant prescription fulfilment and guaranteed product availability. Built in partnership with IhreApotheken.de using their digital infrastructure.
- Canify Services — Contract Manufacturing (CMO) & Market Access Platform Full-service contract manufacturing and EU Market Access Platform for third-party medical cannabis producers, spanning supplier qualification, GMP processing, batch release, BtM/GDP storage, contract logistics, and distribution. Customers include international cannabis cultivators needing a compliant route into the German/European market.
Quantifiable outcome
- Revenue increased 250% year-over-year to €15.5 million in first nine months of 2025
- +1 more outcomes
Companies that use Canify
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Canify technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Canify partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered flagship and core.
- IhreApotheken.de KGaAflagshipLaunch of CATHAROS digital marketplace for medical cannabis in Germany, scheduled for 2026. The platform connects patients directly with pharmacies, leveraging iA.de's existing digital infrastructure of up to 7,500 pharmacies. Both companies will create a pharmacy-centric solution for legally compliant prescriptions.
- MG Health (Lesotho)coreMerger announcement to form an international leading provider for medical cannabis. The combined entity will integrate cultivation, EU-GMP certified production through to patients. MG Health supplies cannabis flowers from Lesotho including cultivars Exodus Cheese, Durban Sky, and others.
- Dopiopharm GmbHcorePartnership to bring Tikun Olam Europe cultivars to the German market. Tikun Olam is a long-established medical cannabis company with roots in Israel. Products include Tikun Erez, Tikun Midnight, Tikun GNC, Tikun Noga, Tikun OZ, and Tikun CAP J cultivars.
- Alveon GmbHcoreJoint venture to develop and globally market an innovative medical device for vaporizing medical cannabis extracts. The partnership combines Canify's cannabis expertise with Alveon's medical technology capabilities.
- MG HealthcoreNew supplier of cannabis flowers from Lesotho. MG Health fulfills Canify's quality requirements and provides ecological and social responsibility through their supply chain engagement. Portfolio includes well-known cultivars returning to the German market.
- SomaicoreCollaboration with Portuguese pharmaceutical company Somai to launch next-generation cannabis extracts on the German market. Extracts feature an additional purification step distinguishing them from other cannabis extracts.
- SOMAI PharmaceuticalscorePartnership for joint marketing of differentiated cannabinoid-based product line in Germany. SOMAI produces cannabis extracts with an additional purification step in their production process. Products sold as 'Somai Canify Cannabisextrakt' in various THC/CBD ratios.
- Phoenix BTMcoreContract logistics and delivery partner for BTM (narcotics) and GDP storage, handling pharmacy distribution in Germany.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Canify competitors and assessment
Company assessmentDirect peers
- Demecan: German medical cannabis producer and distributor with EU-GMP production and direct pharmacy/wholesale relationships. Most direct domestic comparable to Canify given its similar positioning in the German pharmacy-channel.
- Cansativa: Germany's largest independent medical-cannabis B2B platform, distributing to pharmacies and offering its own product lines. Highly comparable as a German distributor/producer using EU-GMP product flows.
- Cantourage: Berlin-based medical cannabis company distributing EU-GMP cannabis flowers and extracts to German pharmacies, with proprietary strains sourced internationally. Direct competitor in the German wholesale channel.
- Sanity Group: Berlin-headquartered medical cannabis company active in cultivation, manufacturing, and distribution in Germany. Comparable vertical scope and German-market focus.
- Cannamedical Pharma: Cologne-based medical cannabis wholesaler supplying German pharmacies with EU-GMP cannabis flowers and extracts from international cultivators. Direct overlap in pharmacy-channel distribution model.
Broad incumbents
- Tilray Brands: Global cannabis major with established EU presence and medical cannabis brands in Germany. Broad incumbent competing in the same end-market with deeper capital and broader product range.
- Aurora Cannabis: Canadian-headquartered global cannabis producer with European medical cannabis operations including Germany. Larger incumbent competing for EU-GMP-certified product share.
- Canopy Growth: Global cannabis major with medical cannabis offerings across Europe. Broad incumbent with scale advantages Canify must compete against for pharmacy and wholesaler mindshare.
- Cronos Group: Global cannabis operator with international medical and consumer offerings, including European distribution. Comparable as a peer in medical-cannabis cross-border distribution and GMP manufacturing.
Emerging players
- Clever Leaves: Colombian-based EU-GMP-certified cannabis cultivator supplying Canify and other European distributors. Both supplier and partial peer given its cultivation-scale and EU-GMP footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Canify social profiles
Digital presenceCanify financial estimates
Financial estimateRevenue estimate
Valuation estimate
Canify leadership team
Management profileNumber of profiles
Profiles12 records
Canify subsidiaries and ownership
Company hierarchySubsidiaries2 records
Canify funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Canify M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Canify
What does Canify do?
Canify AG manufactures and distributes EU-GMP and GDP-certified medical cannabis products — dried cannabis flowers and cannabinoid extracts — to pharmacies and pharmaceutical wholesalers across Europe. In addition to its own product portfolio, the company offers contract manufacturing (CMO) and market-access services for third-party cannabis producers, covering supplier qualification, GMP processing, laboratory analysis, batch release, warehousing, and distribution from its former-NATO-bunker production facility in Leipheim, Germany.
Is Canify a public or private company?
Canify is a private company. It is classified as venture growth investor backed and is currently operating.
When was Canify founded?
Canify was founded in 2022. It employs 11 to 50 people.
Where is Canify based?
Canify is headquartered in Vejle, Denmark, in the Europe region.
How does Canify make money?
Three revenue lines are on record. Medical Cannabis Product Sales are the primary driver. The others are contract Manufacturing Services (CMO) and market Access Platform Services.
Who are Canify's main competitors?
Direct peers on record are Demecan, Cansativa, Cantourage, Sanity Group and Cannamedical Pharma. Broad incumbents are Tilray Brands, Aurora Cannabis, Canopy Growth and Cronos Group. Clever Leaves is listed as an emerging player.
Does Canify have an API?
No public API is recorded for Canify.
What industry is Canify in?
Canify's product category is Medical Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAGAG, Medical Cannabis Delivery & Online Ordering, with a secondary code of CRAOAIAF, Cannabis Wholesale Distribution (Flower, Extracts, Edibles). Its NAICS code is 325411 and its SIC code is 2834.